Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Age
12 - 17 years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0017
Birmingham, Alabama, United States
Local Institution - 0050
Phoenix, Arizona, United States
Local Institution - 0032
Los Angeles, California, United States
Local Institution - 0008
Los Angeles, California, United States
Local Institution - 0033
Palo Alto, California, United States
Local Institution - 0044
San Diego, California, United States
Local Institution - 0038
Aurora, Colorado, United States
Local Institution - 0031
St. Petersburg, Florida, United States
Local Institution - 0053
Atlanta, Georgia, United States
Local Institution - 0013
Chicago, Illinois, United States
Start Date
April 17, 2024
Primary Completion Date
November 25, 2025
Completion Date
March 28, 2031
Last Updated
December 19, 2025
44
ACTUAL participants
Mavacamten
DRUG
Placebo
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT06112743
NCT04418297
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03450252